Challenger Limited (ASX: CGF) – Stock Plunges despite Unveiling Strong Capital Base

teamwork business woman accounting concept financial in office

Challenger Limited (ASX: CGF) has revealed its full year result wherein assets under management increased to more than $81 billion, which is up by 16%. This jump has been well supported by significant growth in Life sales and very strong fund flows in the Funds Management business, over the last five years. Normalized net profit after tax increased to $406 million up by 6%, while statutory net profit after tax, was down to $323 million representing a fall of 19%. This seems to have impacted the investors’ view on this annuity provider.

[optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

Following the $500 million strategic equity placement to MS&AD Insurance Group Holdings, normalized pre-tax return on equity was lower at 16.5%, as forecasted. The full year dividend increased to 35.5 cents per share which is fully franked and up by 0.5 cents. With $1.3 billion of excess regulatory capital, Challenger Life finished the year strongly capitalized.

The stock was trading at a market price of $11.650 and with daily price change of -$0.8 or a percentage change of -6.43% as at August 14, 2018 (2 PM AEST). The stock has seen a performance change of -3.11% over the past 12 months.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


Disclaimer

The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report